Kelyniam Global Inc (KLYG) fair value: what the stock is really worth
As of Oct 30, 2026: fair value (intrinsic value) of Kelyniam Global Inc stock $0.01, price $0.10, upside -90.0%, quality 51 out of 100. Rating: strongly overvalued. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with oneYes, for free
Kelyniam Global, Inc., a medical device manufacturing company, engages in the production of custom prosthetics cranial implants utilizing computer aided design, and computer aided manufacturing of advanced medical grade polymers in the United States.
Show moreShow less
The company is also involved in the development, manufacture, and distribution of custom cranial implant for patients requiring the reconstruction of cranial and facial structures. It serves surgeons, health systems, and payors.
The company was formerly known as Ketner Global Investments, Inc. and changed its name to Kelyniam Global, Inc. in December 2007. Kelyniam Global, Inc. was incorporated in 2005 and is based in Canton, Connecticut.
Stock analysis
Kelyniam Global Inc (KLYG) currently trades at $0.1000, while our model-based Fair Value estimate is $0.0100, 90.0% below the price, so the stock looks overvalued today.
Show more
Valuation
How firm this estimate is: it rests on 1 models at a data quality of 96/100, which puts the data coverage at low.
Scenario range: $0.0100 (bear) to $0.0200 (bull), the price of $0.1000 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 51/100 (solid quality), in the Healthcare sector.
Mixed Growth: Revenue is growing, but margins or cash flow do not fully confirm the trend.
Kelyniam Global Inc reported revenue of $3.1M in FY2025 versus $2.7M in FY2021, a compound +3.5%/yr. Reported net income was −$139K in FY2025.
Key figures
Market cap $5.1M Micro · P/S ratio 1.89 · Net margin −4.5% · Return on equity −31.6% · Return on assets (EBIT) −8.9% · Operating margin 11.3% · Revenue (TTM) $2.7M · Revenue growth (YoY) +13.1%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 17 out of 100 (low confidence).
What moves the price
The share trades about 47% below its 52-week high and 11% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at −8% fair-value upside, at −90%, KLYG screens richer than that median.
Fair Value models
Bear$0.0100Fair Value $0.0100Bull$0.0200
Price $0.1000 · Upside -90.0%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.6/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Revenue growth 1 year
−8.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+0.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+4.0%
Start year 2020 (pandemic). Over 10 years: +7.2% a year
Revenue growth 19 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+22.1%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
3.1% (2020) → −3.5% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 325 stocks
Beats the industry median on 3/9 measures
Overall it trails its industry peers.
Valuation
Quality Score51 · Below median
Fair Value upside−90.0% · Bottom 25%
Profitability
Return on assets−7.9% · Below median
Net margin (12 months)−8.2% · Bottom 25%
Operating margin (12 months)11.3% · Above median
Growth and dividend
Revenue growth (quarter YoY)13.1% · Above median
Balance sheet
Debt / equity0.27× · Above median
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/B6.22× · Priciest 25%
P/S (12 months)1.89× · Cheaper than median
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 10
FUTURE (revenue growth)66· sector 35
PAST (return on equity)0· sector 16
HEALTH (low debt)87· sector 98
DIVIDEND (yield)0· sector 36
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Kelyniam Global Inc Fair Value". https://www.fairvalue-calculator.com/stock/KLYG
Frequently asked questions
Is Kelyniam Global Inc (KLYG) overvalued or undervalued?
As of Oct 30, 2026, our model estimates a fair value of $0.0100 versus a price of $0.1000, about −90% upside (overvalued).
What is the fair value of KLYG?
Our model-based fair value for Kelyniam Global Inc is $0.0100 (as of Oct 30, 2026), built from audited fundamentals. The current price: $0.1000.
What is the quality score of KLYG?
Kelyniam Global Inc has a Quality Score of 51/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Kelyniam Global Inc (KLYG)?
Our model-based price target is the fair value of $0.0100 (as of Oct 30, 2026) from 1 valuation models. Cautious scenario $0.0100, optimistic scenario $0.0200. It is a calculation from audited fundamentals, not an analyst target.
What is the Kelyniam Global Inc stock forecast for 2026?
Our models put fair value at $0.0100, about −90% upside versus a price of $0.1000 (overvalued). Cautious scenario $0.0100, optimistic scenario $0.0200. The calculation is refreshed regularly with new filings.
What is the revenue of Kelyniam Global Inc (KLYG)?
Kelyniam Global Inc reported trailing-twelve-month revenue of about $2.7M (latest available figure, as of Oct 30, 2026).
What is the intrinsic value of Kelyniam Global Inc (KLYG)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Kelyniam Global Inc it is $0.0100 per share (as of Oct 30, 2026), against a price of $0.1000. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Kelyniam Global Inc stock overvalued or undervalued in 2026?
As of Oct 30, 2026, KLYG trades above its calculated fair value: price $0.1000, fair value $0.0100, a gap of about −90% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of KLYG?
No. The price is what the market pays today ($0.1000); the fair value is what the company's own numbers justify ($0.0100). For Kelyniam Global Inc the two are $0.0900 per share apart. That gap is exactly why we show both numbers side by side.
How much is Kelyniam Global Inc worth?
The market values Kelyniam Global Inc at about $5.1M (market capitalisation, as of Oct 30, 2026). Per share that is $0.1000; our models calculate a fair value of $0.0100 per share.
What do the bullish and bearish scenarios say about KLYG?
Our models span a range for Kelyniam Global Inc: cautious scenario $0.0100, base $0.0100, optimistic $0.0200 per share (as of Oct 30, 2026, price $0.1000). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Kelyniam Global Inc (KLYG)?
Balance-sheet figures for Kelyniam Global Inc (as of Oct 30, 2026): return on equity −31.6%, debt of 0.27 per unit of equity. They feed the Quality Score of 51/100, which measures business quality independently of the share price.
How far is KLYG from its 52-week high?
Kelyniam Global Inc trades at $0.1000, about 47% below its 52-week high of $0.1900 and 11% above the low of $0.0900 (as of Oct 30, 2026). Distance from the high says nothing about value: that is what the fair value of $0.0100 is for.
Which stocks are comparable to Kelyniam Global Inc?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Kelyniam Global Inc stock attractive at the current price?
The data as of Oct 30, 2026: price $0.1000, calculated fair value $0.0100 (−90%), Quality Score 51/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of KLYG calculated?
We run Kelyniam Global Inc through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $0.0100, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.4 % above its aggregate fair value. Kelyniam Global Inc itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Kelyniam Global Inc (KLYG)?
The closing price on Oct 30, 2026 was $0.1000. Our model-based fair value is $0.0100, about −90% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Kelyniam Global Inc right now?
The price sits above even our optimistic bull case ($0.0200). The favourable scenario is already priced in. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. Solid but not exceptional quality (51/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range ($0.0100 to $0.0200) leaves room in how you read the outcome.
Key figures of Kelyniam Global Inc
How large is the market capitalisation of Kelyniam Global Inc (KLYG)?
The market capitalisation of Kelyniam Global Inc is $5.1M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Kelyniam Global Inc (KLYG)?
The price-to-sales ratio of Kelyniam Global Inc is 1.89 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What is the net margin of Kelyniam Global Inc (KLYG)?
The net margin of Kelyniam Global Inc is −4.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Kelyniam Global Inc (KLYG)?
The return on equity (ROE) of Kelyniam Global Inc is −31.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Kelyniam Global Inc (KLYG)?
On an EBIT basis the return on assets of Kelyniam Global Inc is −8.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Kelyniam Global Inc (KLYG)?
The operating margin of Kelyniam Global Inc is 11.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Kelyniam Global Inc (KLYG)?
Revenue at Kelyniam Global Inc is growing +13.1% versus a year earlier (3y avg +0.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Kelyniam Global Inc (KLYG)?
Earnings per share at Kelyniam Global Inc are growing +465% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Kelyniam Global Inc (KLYG) generate?
The free cash flow of Kelyniam Global Inc is −$194K (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Kelyniam Global Inc (KLYG) carry?
The net debt of Kelyniam Global Inc is $404K (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Kelyniam Global Inc in the live analysis
One click puts Kelyniam Global Inc on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 28,000+ stock screener.
Thin data
Oct 30, 2026